Turn's Science and Technology
IL-36 sits upstream of multiple inflammatory pathways that drive eczema severity. When IL-36 signaling increases, downstream cytokines such as IL-31 and IL-4 rise sharply, intensifying itch, inflammation, and barrier dysfunction.
Addressing the Inflammatory Cascade at Its Source
IL-36 sits upstream of multiple inflammatory pathways that drive eczema severity. When IL-36 signaling increases, downstream cytokines such as IL-31 and IL-4 rise sharply, intensifying itch, inflammation, and barrier dysfunction.
GX-03 is designed to modulate these cytokines within the skin where the disease occurs.
GX-03 has demonstrated inhibition of key inflammatory drivers including IL-36α, IL-36γ, IL-31, and IL-4. These cytokines are central to the inflammatory loop that fuels redness, itch, and chronic skin damage. GX-03 achieves meaningful cytokine modulation without needles, immune suppression, or systemic drug burden.
IL-36 acts early in the inflammatory cascade, activating downstream pathways that amplify redness, flare cycles, and the chronic immune response in the skin. Inhibiting these signals at the site of disease helps interrupt the upstream drivers that make inflammatory skin disease persistent and difficult to control.
IL-4 and IL-31 play a different but equally important role. These cytokines are closely linked to the itch–scratch cycle, barrier breakdown, and escalating disease burden. Reducing IL-4 and IL-31 locally can interrupt the cycle that turns everyday itch into chronic inflammation, nighttime scratching, sleep loss, and significant quality-of-life impact for patients and families.
By targeting IL-36α, IL-36γ, IL-4, and IL-31 where they operate-in the skin-GX-03 aims to address both the biologic core of the disease and the real-world burden that drives suffering and disease progression, all without systemic exposure or injections.
PermaFusion®: Our Proprietary Drug Delivery Platform
At the core of Turn Therapeutics is PermaFusion, our proprietary drug delivery platform. PermaFusion enables water-soluble therapeutic agents to penetrate deeper tissue layers without emulsifiers, adjuvants, or unnecessary additives.
This capability allows us to design therapies that deliver meaningful concentrations of active agents precisely where they are needed, whether in skin, nail, or mucosal tissue, while minimizing off-target exposure.
PermaFusion underpins both our therapeutic pipeline and our proven regulatory execution.
GX-03 builds on the proven PermaFusion® platform, incorporating targeted cytokine modulators (IL-36, IL-31, IL-4) into the base formulation. This represents an evolution from our FDA-cleared medical devices to an investigational, first-in-class topical immunotherapy for moderate to severe eczema that has demonstrated a consistent and predictable adverse event profile in early clinical studies.
Traditional topical formulations have limited ability to deliver water-soluble molecules across the skin’s lipid-rich barrier. PermaFusion® addresses this by using a proprietary mixing process to create stable suspensions in–oil-based dispersions, improving dermal penetration and enabling the topical delivery of molecules that typically require administration by injection.
How it Works
Traditional topical formulations have limited ability to deliver water-soluble molecules across the skin’s lipid-rich barrier. PermaFusion® addresses this by using a proprietary mixing process to create stable suspensions in–oil-based dispersions, improving dermal penetration and enabling the topical delivery of molecules that typically require administration by injection.
PermaFusion®:
- Preserves normal immune function with predictable, low adverse-event profile
- Enables topical delivery of biologic-level therapeutics without needles or systemic exposure
- Intervenes at earliest molecular events before chronic inflammation becomes self-sustaining
- Precision cytokine modulation (IL-36, IL-31, IL-4) targeting upstream inflammatory cascade disrupting the eczema loop as well as downstream modulation of symptoms
